Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 39NET 27Gastrointestinal 6Thoracic 3CNS 3Head & Neck 2Gynecologic 2Sarcoma 1Other solid neoplasm 1Lymphoid 1Genitourinary 1

Conditions

Lymphoma 900Lymphoma, Non-Hodgkin 685Leukemia, Lymphocytic, Chronic, B-Cell 665Lymphoma, Large B-Cell, Diffuse 617Precursor Cell Lymphoblastic Leukemia-Lymphoma 605Lymphoma, Follicular 516Hodgkin Disease 442Lymphoma, Mantle-Cell 421Leukemia 410Lymphoma, B-Cell, Marginal Zone 289Burkitt Lymphoma 285Recurrence 277Leukemia, Myeloid, Acute 276Multiple Myeloma 250Myelodysplastic Syndromes 237Waldenstrom Macroglobulinemia 187Lymphoma, B-Cell 179Lymphoma, Large-Cell, Immunoblastic 153Lymphoma, T-Cell, Cutaneous 143Leukemia, Myelogenous, Chronic, BCR-ABL Positive 127Lymphoma, T-Cell, Peripheral 123Mycosis Fungoides 118Myeloproliferative Disorders 112Lymphoma, Large-Cell, Anaplastic 107Dendritic Cell Sarcoma, Interdigitating 103Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 102Neoplasms 98Lymphoma, Extranodal NK-T-Cell 96Hematologic Neoplasms 96Sezary Syndrome 94

Interventions

ganitumab 1conatumumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoid Tumor × Lymphoid × Clear all
NCT01327612 2021-02-21

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

Amgen

Phase 2 Completed
12 enrolled 21 charts
EndocrineGastrointestinalLymphoidSarcomaThoracic

Carcinoid Tumor, Carcinoma, Non-Small-Cell Lung, Lymphoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡